Smith & Nephew plc · LSE:SN.

Smith & Nephew — J.P. Morgan Healthcare Conference 2012

16 slides from Smith & Nephew's conference presentation, Jan 9, 2012

  1. Slide 1: J.P. Morgan Healthcare Conference

    J.P. Morgan Healthcare Conference 9 January 2012 Olivier Bohuon ‟ Chief Executive Officer

  2. Slide 2: Forward looking statements

    Forward looking statements This document contains certain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan"

  3. Slide 3: Overview of Smith & Nephew

    Overview of Smith & Nephew 2010 Advanced Wound Sales $3,962m Management Trading profit $969m Advanced treatments Margin 24.5% for hard to heal wounds Sales $912m 22% 57% Orthopaedics Endoscopy - Reconstruction ($1,537m) Products for minimally 21% Hip, knee & shoulder products invasive surgery - Trau

  4. Slide 4: Geographical Sales

    Geographical Sales 2011 Q3 YTD sales growth USA 4% Europe 2% ROW 10% Rest of the world 24% USA 43% 26% Continental Europe 7% UK Data : 2010 revenues ROW includes Japan, Australia, New Zealand & Canada 4

  5. Slide 5: Market - Long term growth drivers continue

    Market ‟ Long term growth drivers continue Orthopaedics Endoscopy AWM Demographics    Prevalence - Osteoarthritis   - Obesity    - Diabetes   “By 2050, the number of Lifestyle people over the age of 65 - Activity levels   around the world will have ‐ Quality of life    tripled to near

  6. Slide 6: New Strategic Priorities

    >t smith&nephew New Strategic Priorities

  7. Slide 7: Strong foundations, but market challenges exist

    Strong foundations, but market challenges exist „ Some cyclical challenges, some structural „ Market concentration with higher competitive Share of Voice „ Environment is difficult/complex ‟ Price erosion ‟ Reimbursement ‟ Outcomes ‟ Complexity of systems in place „ Growth in mature markets slowing

  8. Slide 8: New Strategic Priorities

    New Strategic Priorities „ Established markets „ Emerging markets „ Innovate for value „ Simplify and improve our operating model „ Supplement the organic growth through acquisitions 8

  9. Slide 9: Existing growth drivers - NPWT

    Existing growth drivers - NPWT RENASYS ™ PICO™ Website: www.mypico.co 9

  10. Slide 10: Emerging markets growth

    Emerging markets growth „ Structure: Emerging International Markets Markets Focused Other „ Countries/regions: China, India, Brazil, Central and Latin Russia America, Eastern Europe, MENA, South Africa, South East Asia, South Korea, etc. „ Products Entire S&N product portfolio 10

  11. Slide 11: R&D investment and direction

    R&D investment and direction „ Current R&D Model ‟ 2010 $151m „ Going forward ‟ Greater discipline in resource allocation ‟ Increase in resources „ Focused investment ‟ Emerging markets ‟ Minimally invasive, particularly biomaterials ‟ Patient matched ‟ NPWT 11

  12. Slide 12: Simplified operating model

    Simplified operating model Emerging International Established Markets1 Markets3 Markets Advanced2 Advanced Focused Other Surgical Wound Devices Management R&D Marketing/Regulations Global functions Notes 1. US, Canada, Europe, Japan, Australia and New Zealand 2. Orthopaedic Reconstruction, Sports Me

  13. Slide 13: Liberating resources (1)

    Liberating resources (1) Expense Actions Cost of goods Review manufacturing facility portfolio Further improvements in manufacturing processes Product portfolio rationalisation Continue field based capital improvement 13

  14. Slide 14: Liberating resources (2)

    Liberating resources (2) Expense Actions Sales force Continue with customer specific sales channels productivity Review and optimise our European sales structure General and Efficiencies from combination of Orthopaedics and Endoscopy Administrative ‟ streamline US operations expenses ‟ assessing str

  15. Slide 15: Growth through acquisitions

    Growth through acquisitions • Organic growth needs to be supplemented by acquisitions • Strong platform to make acquisitions ‟ Management strength / capability ‟ Platform is ready (sales channels, operations/logistics) ‟ Financial strength • Actively looking for opportunities 15

  16. Slide 16: We are smith&nephew

    +“ We are smith&nephew

Smith & Nephew — J.P. Morgan Healthcare Conference 2012 on 6ix